Although the costs of the ER/PR/HER2 tests are relatively low, around €100 for an IHC and between €300 and 400 for an ISH [11, 12], the cumulative costs of the use of such tests can still be high given the large number of patients yearly diagnosed with breast cancer. The gene discussed is ERBB2; the disease is breast cancer.